Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas

Hsueh Li Tan, Michael C. Haffner, David M. Esopi, Ajay M. Vaghasia, Giovanna A. Giannico, Hillary M. Ross, Susmita Ghosh, Jessica L. Hicks, Qizhi Zheng, Ankur R. Sangoi, S Yegnasubramanian, Adeboye O. Osunkoya, Angelo Michael Demarzo, Jonathan Ira Epstein, Tamara Lotan

Research output: Contribution to journalArticle

Abstract

We have described a rare group of prostate adenocarcinomas that show aberrant expression of p63, a protein strongly expressed in prostatic basal cells and absent from usual-type acinar prostate cancers. The partial basal-like immunophenotype of these tumors is intriguing in light of the persistent debate surrounding the cell-of-origin for prostate cancer; however, their molecular phenotype is unknown. We collected 37 of these tumors on radical prostatectomy and biopsy and assessed subsets for a diverse panel of molecular markers. The majority of p63-expressing tumors were positive for the ΔNp63 isoform (6/7) by immunofluorescence and p63 mRNA (7/8) by chromogenic in situ hybridization. Despite p63 positivity, these tumors uniformly expressed luminal-type cytokeratin proteins such as CK18 (13/13), CK8 (8/8), and markers of androgen axis signaling commonly seen in luminal cells, including androgen receptor (10/11), NKX3.1 (8/8), and prostein (12/13). Conversely, basal cytokeratins such as CK14 and CK15 were negative in all cases (0/8) and CK5/6 was weakly and focally positive in 36% (4/11) of cases. Pluripotency markers including β-catenin, Oct4, and c-kit were negative in p63-expressing tumors (0/11). Despite nearly universal expression of androgen receptor and downstream androgen signaling targets, p63-expressing tumors lacked ERG rearrangements by fluorescence in situ hybridization (0/14) and ERG protein expression (0/37). No tumors expressed SPINK1 or showed PTEN protein loss (0/19). Surprisingly, 74% (14/19) of p63-expressing tumors expressed GSTP1 protein at least focally, and 33% (2/6) entirely lacked GSTP1 CpG island hypermethylation by bisulfite sequencing. In contrast to usual prostatic adenocarcinomas, prostate tumors with p63 expression show a mixed luminal/basal immunophenotype, uniformly lack ERG gene rearrangement, and frequently express GSTP1. These data strongly suggest that p63-expressing prostate tumors represent a molecularly distinct subclass and further study of this rare tumor type may yield important insights into the role of p63 in prostatic biology and the prostate cancer cell-of-origin.

Original languageEnglish (US)
Pages (from-to)446-456
Number of pages11
JournalModern Pathology
Volume28
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Prostate
Adenocarcinoma
Neoplasms
Prostatic Neoplasms
Androgen Receptors
Keratins
Androgens
Proteins
PTEN Phosphohydrolase
Catenins
CpG Islands
Gene Rearrangement
Prostatectomy
Fluorescence In Situ Hybridization
In Situ Hybridization
Fluorescent Antibody Technique
Protein Isoforms
Phenotype
Biopsy
Messenger RNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. / Tan, Hsueh Li; Haffner, Michael C.; Esopi, David M.; Vaghasia, Ajay M.; Giannico, Giovanna A.; Ross, Hillary M.; Ghosh, Susmita; Hicks, Jessica L.; Zheng, Qizhi; Sangoi, Ankur R.; Yegnasubramanian, S; Osunkoya, Adeboye O.; Demarzo, Angelo Michael; Epstein, Jonathan Ira; Lotan, Tamara.

In: Modern Pathology, Vol. 28, No. 3, 01.03.2015, p. 446-456.

Research output: Contribution to journalArticle

Tan, HL, Haffner, MC, Esopi, DM, Vaghasia, AM, Giannico, GA, Ross, HM, Ghosh, S, Hicks, JL, Zheng, Q, Sangoi, AR, Yegnasubramanian, S, Osunkoya, AO, Demarzo, AM, Epstein, JI & Lotan, T 2015, 'Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas', Modern Pathology, vol. 28, no. 3, pp. 446-456. https://doi.org/10.1038/modpathol.2014.115
Tan, Hsueh Li ; Haffner, Michael C. ; Esopi, David M. ; Vaghasia, Ajay M. ; Giannico, Giovanna A. ; Ross, Hillary M. ; Ghosh, Susmita ; Hicks, Jessica L. ; Zheng, Qizhi ; Sangoi, Ankur R. ; Yegnasubramanian, S ; Osunkoya, Adeboye O. ; Demarzo, Angelo Michael ; Epstein, Jonathan Ira ; Lotan, Tamara. / Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. In: Modern Pathology. 2015 ; Vol. 28, No. 3. pp. 446-456.
@article{ded7eab0fc7e4630a7fae7f0d9c48edc,
title = "Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas",
abstract = "We have described a rare group of prostate adenocarcinomas that show aberrant expression of p63, a protein strongly expressed in prostatic basal cells and absent from usual-type acinar prostate cancers. The partial basal-like immunophenotype of these tumors is intriguing in light of the persistent debate surrounding the cell-of-origin for prostate cancer; however, their molecular phenotype is unknown. We collected 37 of these tumors on radical prostatectomy and biopsy and assessed subsets for a diverse panel of molecular markers. The majority of p63-expressing tumors were positive for the ΔNp63 isoform (6/7) by immunofluorescence and p63 mRNA (7/8) by chromogenic in situ hybridization. Despite p63 positivity, these tumors uniformly expressed luminal-type cytokeratin proteins such as CK18 (13/13), CK8 (8/8), and markers of androgen axis signaling commonly seen in luminal cells, including androgen receptor (10/11), NKX3.1 (8/8), and prostein (12/13). Conversely, basal cytokeratins such as CK14 and CK15 were negative in all cases (0/8) and CK5/6 was weakly and focally positive in 36{\%} (4/11) of cases. Pluripotency markers including β-catenin, Oct4, and c-kit were negative in p63-expressing tumors (0/11). Despite nearly universal expression of androgen receptor and downstream androgen signaling targets, p63-expressing tumors lacked ERG rearrangements by fluorescence in situ hybridization (0/14) and ERG protein expression (0/37). No tumors expressed SPINK1 or showed PTEN protein loss (0/19). Surprisingly, 74{\%} (14/19) of p63-expressing tumors expressed GSTP1 protein at least focally, and 33{\%} (2/6) entirely lacked GSTP1 CpG island hypermethylation by bisulfite sequencing. In contrast to usual prostatic adenocarcinomas, prostate tumors with p63 expression show a mixed luminal/basal immunophenotype, uniformly lack ERG gene rearrangement, and frequently express GSTP1. These data strongly suggest that p63-expressing prostate tumors represent a molecularly distinct subclass and further study of this rare tumor type may yield important insights into the role of p63 in prostatic biology and the prostate cancer cell-of-origin.",
author = "Tan, {Hsueh Li} and Haffner, {Michael C.} and Esopi, {David M.} and Vaghasia, {Ajay M.} and Giannico, {Giovanna A.} and Ross, {Hillary M.} and Susmita Ghosh and Hicks, {Jessica L.} and Qizhi Zheng and Sangoi, {Ankur R.} and S Yegnasubramanian and Osunkoya, {Adeboye O.} and Demarzo, {Angelo Michael} and Epstein, {Jonathan Ira} and Tamara Lotan",
year = "2015",
month = "3",
day = "1",
doi = "10.1038/modpathol.2014.115",
language = "English (US)",
volume = "28",
pages = "446--456",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas

AU - Tan, Hsueh Li

AU - Haffner, Michael C.

AU - Esopi, David M.

AU - Vaghasia, Ajay M.

AU - Giannico, Giovanna A.

AU - Ross, Hillary M.

AU - Ghosh, Susmita

AU - Hicks, Jessica L.

AU - Zheng, Qizhi

AU - Sangoi, Ankur R.

AU - Yegnasubramanian, S

AU - Osunkoya, Adeboye O.

AU - Demarzo, Angelo Michael

AU - Epstein, Jonathan Ira

AU - Lotan, Tamara

PY - 2015/3/1

Y1 - 2015/3/1

N2 - We have described a rare group of prostate adenocarcinomas that show aberrant expression of p63, a protein strongly expressed in prostatic basal cells and absent from usual-type acinar prostate cancers. The partial basal-like immunophenotype of these tumors is intriguing in light of the persistent debate surrounding the cell-of-origin for prostate cancer; however, their molecular phenotype is unknown. We collected 37 of these tumors on radical prostatectomy and biopsy and assessed subsets for a diverse panel of molecular markers. The majority of p63-expressing tumors were positive for the ΔNp63 isoform (6/7) by immunofluorescence and p63 mRNA (7/8) by chromogenic in situ hybridization. Despite p63 positivity, these tumors uniformly expressed luminal-type cytokeratin proteins such as CK18 (13/13), CK8 (8/8), and markers of androgen axis signaling commonly seen in luminal cells, including androgen receptor (10/11), NKX3.1 (8/8), and prostein (12/13). Conversely, basal cytokeratins such as CK14 and CK15 were negative in all cases (0/8) and CK5/6 was weakly and focally positive in 36% (4/11) of cases. Pluripotency markers including β-catenin, Oct4, and c-kit were negative in p63-expressing tumors (0/11). Despite nearly universal expression of androgen receptor and downstream androgen signaling targets, p63-expressing tumors lacked ERG rearrangements by fluorescence in situ hybridization (0/14) and ERG protein expression (0/37). No tumors expressed SPINK1 or showed PTEN protein loss (0/19). Surprisingly, 74% (14/19) of p63-expressing tumors expressed GSTP1 protein at least focally, and 33% (2/6) entirely lacked GSTP1 CpG island hypermethylation by bisulfite sequencing. In contrast to usual prostatic adenocarcinomas, prostate tumors with p63 expression show a mixed luminal/basal immunophenotype, uniformly lack ERG gene rearrangement, and frequently express GSTP1. These data strongly suggest that p63-expressing prostate tumors represent a molecularly distinct subclass and further study of this rare tumor type may yield important insights into the role of p63 in prostatic biology and the prostate cancer cell-of-origin.

AB - We have described a rare group of prostate adenocarcinomas that show aberrant expression of p63, a protein strongly expressed in prostatic basal cells and absent from usual-type acinar prostate cancers. The partial basal-like immunophenotype of these tumors is intriguing in light of the persistent debate surrounding the cell-of-origin for prostate cancer; however, their molecular phenotype is unknown. We collected 37 of these tumors on radical prostatectomy and biopsy and assessed subsets for a diverse panel of molecular markers. The majority of p63-expressing tumors were positive for the ΔNp63 isoform (6/7) by immunofluorescence and p63 mRNA (7/8) by chromogenic in situ hybridization. Despite p63 positivity, these tumors uniformly expressed luminal-type cytokeratin proteins such as CK18 (13/13), CK8 (8/8), and markers of androgen axis signaling commonly seen in luminal cells, including androgen receptor (10/11), NKX3.1 (8/8), and prostein (12/13). Conversely, basal cytokeratins such as CK14 and CK15 were negative in all cases (0/8) and CK5/6 was weakly and focally positive in 36% (4/11) of cases. Pluripotency markers including β-catenin, Oct4, and c-kit were negative in p63-expressing tumors (0/11). Despite nearly universal expression of androgen receptor and downstream androgen signaling targets, p63-expressing tumors lacked ERG rearrangements by fluorescence in situ hybridization (0/14) and ERG protein expression (0/37). No tumors expressed SPINK1 or showed PTEN protein loss (0/19). Surprisingly, 74% (14/19) of p63-expressing tumors expressed GSTP1 protein at least focally, and 33% (2/6) entirely lacked GSTP1 CpG island hypermethylation by bisulfite sequencing. In contrast to usual prostatic adenocarcinomas, prostate tumors with p63 expression show a mixed luminal/basal immunophenotype, uniformly lack ERG gene rearrangement, and frequently express GSTP1. These data strongly suggest that p63-expressing prostate tumors represent a molecularly distinct subclass and further study of this rare tumor type may yield important insights into the role of p63 in prostatic biology and the prostate cancer cell-of-origin.

UR - http://www.scopus.com/inward/record.url?scp=84929613815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929613815&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2014.115

DO - 10.1038/modpathol.2014.115

M3 - Article

VL - 28

SP - 446

EP - 456

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 3

ER -